GLP-1 fusion peptides, their production and use

US8431533B2 · kind B2 · utility

Assignee

• Biocompatibles UK Limited · GB

Inventors

• Peter Geigle · Alzenau, DE
• Christine Wallrapp · Großostheim, DE
• Eric Thoenes · Büdingen, DE

Key dates

• Filing date: Sep 22, 2006
• Grant date: Apr 30, 2013
• Expiry date: Feb 3, 2029

Classification

• Technology area (CPC G): Physics
• CPC primary: G07F11/165
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1 (7-35, 7-36 or 7-37) sequence and as component (II)C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1 (7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.